The FDA has approved SIGNOS, a glucose monitoring system from Cygnos, specifically designed for weight loss, providing a new option for managing obesity beyond traditional treatments like GLP-1 drugs and surgeries, which are often inaccessible due to high costs and insurance restrictions. SIGNOS allows anyone, regardless of their weight, to access its services, focusing on personalized real-time data and lifestyle recommendations to aid in weight management.
Currently, almost 74% of Americans are overweight or obese, costing the U.S. healthcare system over $170 billion annually. SIGNOS memberships are available in 3- or 6-month plans at $139 or $129, respectively, and include continuous glucose monitors (CGMs). While insurance does not yet cover the system, it is significantly cheaper than GLP-1 medications. The SIGNOS system can complement other treatments and is designed to help users understand their body’s responses to food and exercise, promoting long-term behavioral changes for weight management.
CEO Sharam Fouladgar-Mercer noted significant interest in the system, which has already seen tens of thousands of trial users, and emphasized its potential impact on the obesity epidemic.
Source link
